Overview of green tea interaction with cardiovascular drugs

José P. Werba, Shingen Misaka, Monica G. Giroli, Shizuo Yamada, Viviana Cavalca, Keisuke Kawabe, Isabella Squellerio, Federica Laguzzi, Satomi Onoue, Fabrizio Veglia, Veronika Myasoedova, Kazuhiko Takeuchi, Eisuke Adachi, Naoki Inui, Elena Tremoli, Hiroshi Watanabe

Research output: Contribution to journalArticle

Abstract

Sensitive to the massive diffusion of purported metabolic and cardiovascular positive effects of green tea and catechin-containing extracts, many consumers of cardiovascular drugs assume these products as a “natural” and presumably innocuous adjunctive way to increase their overall health. However, green tea may interfere with the oral bioavailability or activity of cardiovascular drugs by various mechanisms, potentially leading to reduced drug efficacy or increased drug toxicity. Available data about interactions between green tea and cardiovascular drugs in humans, updated in this review, are limited so far to warfarin, simvastatin and nadolol, and suggest that the average effects are mild to modest. Nevertheless, in cases of unexpected drug response or intolerance, it is warranted to consider a possible green tea-drug interaction, especially in people who assume large volumes of green tea and/or catechin-enriched products with the conviction that “more-is-better”.

Original languageEnglish
Pages (from-to)1213-1219
Number of pages7
JournalCurrent Pharmaceutical Design
Volume21
Issue number9
Publication statusPublished - Jan 1 2015

    Fingerprint

Keywords

  • Cardiovascular drugs
  • Catechins
  • Dietary-drug interaction
  • Green tea
  • Herb-drug interaction
  • Nadolol
  • Simvastatin
  • Warfarin

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Medicine(all)

Cite this

Werba, J. P., Misaka, S., Giroli, M. G., Yamada, S., Cavalca, V., Kawabe, K., Squellerio, I., Laguzzi, F., Onoue, S., Veglia, F., Myasoedova, V., Takeuchi, K., Adachi, E., Inui, N., Tremoli, E., & Watanabe, H. (2015). Overview of green tea interaction with cardiovascular drugs. Current Pharmaceutical Design, 21(9), 1213-1219.